Filing Analysis
Invivyd, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026, and provided recent business highlights via a press release.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an emerging growth company
Invivyd, Inc. received a deficiency letter from Nasdaq because its common stock closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until January 19, 2027, to regain compliance through the initial compliance period.
🚩 Red Flags
- Delisting notice/deficiency letter from Nasdaq
- Stock price performance significantly below $1.00 threshold
- Risk of mandatory transfer to the Nasdaq Capital Market if compliance is not met
📋 Key Facts
- Received deficiency letter from Nasdaq on July 23, 2026.
- Violation: Bid price closed below $1.00 for 30 consecutive business days (Nasdaq Listing Rule 5450(a)(1)).
- Initial Compliance Period deadline: January 19, 2027.
- Requirement to regain compliance: Closing bid price must be at least $1.00 for at least ten consecutive business days during the period.
- Potential Second Compliance Period (180 days) requires transfer to Nasdaq Capital Market and meeting market value requirements.
Invivyd, Inc. announced that the U.S. FDA has provided a twelve-month advanced notice of Emergency Use Authorization (EUA) termination for its product PEMGARDA®. The company is currently working with the FDA on next steps regarding the product's regulatory status.
🚩 Red Flags
- Loss of Emergency Use Authorization (EUA) status for a primary product represents a significant regulatory setback and potential revenue risk.
- Regulatory uncertainty regarding the future commercialization path of PEMGARDA®.
📋 Key Facts
- The FDA issued a 12-month advance notice of termination for the Emergency Use Authorization (EUA) of PEMGARDA®.
- Notice date: July 6, 2026.
- The company is actively engaging with the FDA regarding next steps for the product.
Invivyd, Inc. announced that its vaccine-alternative antibody, VYD2311, has received Fast Track Designation from the FDA to prevent COVID.
📋 Key Facts
- Date of event: December 23, 2025
- Product: VYD2311 (a vaccine-alternative antibody)
- Regulatory Milestone: Received FDA Fast Track Designation for COVID prevention
- The filing includes a press release as Exhibit 99.1
Invivyd, Inc. announced the selection of a potential best-in-class RSV antibody candidate, VBY329, with a target for IND (Investigational New Drug) readiness in the second half of 2026.
📋 Key Facts
- Selected VBY329 as a potential best-in-class RSV antibody candidate.
- Targeting IND readiness for VBY329 in 2H 2026.
- The announcement was made via press release on November 24, 2025.
Invivyd, Inc. completed a public offering of 44 million shares of common stock and 6 million pre-funded warrants at approximately $2.50 per share, raising net proceeds of roughly $117.2 million.
🚩 Red Flags
- Significant dilution: The issuance of 44 million new shares represents a substantial increase in the total share count.
- Use of pre-funded warrants: Often used by institutional investors to avoid immediate ownership thresholds (e.g., 5% or 10%) while securing economic interest.
📋 Key Facts
- Offered 44,000,000 shares of common stock at $2.50 per share.
- Issued 6,000,000 pre-funded warrants at $2.4999 per warrant.
- Underwriters included Cantor Fitzgerald & Co. as representative.
- Net proceeds to the company are approximately $117.2 million after expenses and discounts.
- The offering closed on November 19, 2025.
- Underwriters have a 30-day option to purchase up to an additional 7,500,000 shares.
Invivyd, Inc. filed an 8-K to announce its quarterly financial results for the period ending September 30, 2025, and provided an updated corporate presentation.
📋 Key Facts
- Announced financial results for the quarter ended September 30, 2025 (Item 2.02).
- Released an updated corporate presentation via its website (Item 8.01).
- Filed as an Emerging Growth Company.
Invivyd, Inc. filed an 8-K to announce the posting of a new investor presentation on its corporate website dated October 30, 2025.
📋 Key Facts
- The company released an updated investor presentation via Exhibit 99.1.
- Filing date is October 30, 2025.
- The registrant is classified as an 'emerging growth company'.
Invivyd, Inc. announced a significant regulatory milestone regarding its VYD2311 clinical program. The company received U.S. IND Clearance and achieved alignment with the FDA on its pivotal clinical program for this COVID-19 antibody treatment.
📋 Key Facts
- Date of event: October 6, 2025
- Company announced U.S. IND (Investigational New Drug) clearance for VYD2311.
- The company reached alignment with the U.S. FDA regarding its pivotal clinical program design.
- VYD2311 is described as a 'vaccine-alternative antibody' intended to prevent COVID.
Invivyd, Inc. announced the appointment of Dr. Paul B. Bolno to its Board of Directors and Compensation Committee following the resignation of Christine Akinc. Additionally, the company successfully regained compliance with Nasdaq's minimum bid price requirement.
🚩 Red Flags
- Recent history of delisting risk due to stock price falling below $1.00 (though compliance has been regained).
📋 Key Facts
- Dr. Paul B. Bolno appointed as Director and to the Compensation Committee, effective September 22, 2025.
- Christine Akinc resigned from the Board and all committees effective September 22, 2025; resignation was not due to any disagreement with the company.
- Dr. Bolno's compensation includes a $40,000 annual cash retainer for Board service and a $5,000 annual cash retainer for Compensation Committee service.
- Dr. Bolno granted 100,000 nonqualified stock options vesting over three years.
- Nasdaq confirmed the company has regained compliance with the minimum bid price requirement (Rule 5450(a)(1)).
- The matter regarding the $1.00 minimum bid price deficiency is now considered closed by Nasdaq.
Invivyd, Inc. completed a significant public offering of common stock and pre-funded warrants to raise approximately $53.5 million in net proceeds. The offering was priced at $0.52 per share, resulting in substantial potential dilution for existing shareholders.
🚩 Red Flags
- Significant dilution: The issuance of over 89 million total securities (including warrants) at a low price point ($0.52) will significantly dilute existing shareholders.
- Low share price: Pricing at $0.52 suggests the company is operating in a highly distressed or micro-cap valuation range, often indicative of high cash burn requirements.
📋 Key Facts
- Total shares offered: 74,811,404 common shares and 21,342,442 pre-funded warrants.
- Offering price: $0.52 per share; Pre-Funded Warrants priced at $0.5199.
- Underwriters exercised their full option to purchase an additional 14,423,076 shares on August 21, 2025.
- Net proceeds from the offering (including over-allotment) totaled approximately $53.5 million.
- The offering closed on August 22, 2025.
- Proceeds are earmarked for VYD2311 clinical program, RSV and measles R&D, SPEAR Study Group efforts, and working capital.
Invivyd, Inc. announced its quarterly financial results for the period ending June 30, 2025, and reported a significant regulatory development regarding a rapid pathway to FDA approval for its monoclonal antibody VYD2311.
📋 Key Facts
- Released Q2 2025 financial results (quarter ended June 30, 2025).
- Announced alignment with the U.S. FDA on a rapid pathway to Full Approval (BLA) for VYD2311.
- VYD2311 is a vaccine alternative monoclonal antibody designed to protect adults and adolescents from COVID-19.
- Updated corporate presentation released via Exhibit 99.3.
Invivyd, Inc. announced the formation of the SPEAR (Spike Protein Elimination and Recovery) Study Group to investigate monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.
📋 Key Facts
- Formation of the 'SPEAR' Study Group involving Invivyd and leading researchers.
- Study focus: Assessing effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.
- Filing date: July 2, 2025.
Invivyd, Inc. issued an 8-K to announce positive full Phase 1/2 clinical data for its next-generation COVID-19 monoclonal antibody, VYD2311.
📋 Key Facts
- Announcement date: June 26, 2025
- Subject: Positive Full Phase 1/2 Clinical Data for VYD2311
- Indication: Potential use as a non-vaccine preventative and for treatment of active COVID-19 infection
- Drug Type: Next generation monoclonal antibody
Invivyd, Inc. held its Annual Meeting of Stockholders on May 20, 2025. The meeting resulted in the election of six directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2025.
📋 Key Facts
- Annual Meeting held on May 20, 2025.
- Six directors elected: Tamsin Berry, Marc Elia, Christine Lindenboom, Terrance McGuire, Kevin F. McLaughlin, and Ajay Royan.
- PricewaterhouseCoopers LLP ratified as independent registered public accounting firm for the fiscal year ending Dec 31, 2025.
- Director elections received significant 'For' votes, with Tamsin Berry receiving the highest count (75,934,285).
Invivyd, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025, and provided an updated corporate presentation.
📋 Key Facts
- Announced financial results for the fiscal quarter ended March 31, 2025.
- Released an updated corporate presentation via Exhibit 99.2.
- The filing is categorized under Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events).
Invivyd, Inc. announced the launch of a new pipeline discovery program specifically targeting monoclonal antibody treatments for Measles. This is an informational update regarding the company's R&D direction.
📋 Key Facts
- Announcement date: May 12, 2025
- Focus area: New Pipeline Discovery Program
- Target indication: Monoclonal Antibody Treatment for Measles
- Filing type: Item 8.01 (Other Events)
Invivyd, Inc. received a deficiency letter from Nasdaq notifying the company that its common stock has fallen below the $1.00 minimum bid price requirement for 30 consecutive business days. The company is currently in an initial compliance period to regain its listing on the Nasdaq Global Market.
🚩 Red Flags
- Non-compliance with Nasdaq's Minimum Bid Price Requirement ($1.00).
- Risk of delisting from the Nasdaq Global Market.
- Potential requirement to transfer to the lower-tier Nasdaq Capital Market if compliance is not met.
📋 Key Facts
- Received deficiency letter from Nasdaq on April 21, 2025.
- The stock closed below $1.00 for 30 consecutive business days.
- Initial Compliance Period ends October 20, 2025.
- To regain compliance, the closing bid price must be at least $1.00 for 10 consecutive business days during the period.
- A second 180-day compliance period may be available if the company transfers to the Nasdaq Capital Market.
Invivyd, Inc. entered into a $30 million senior secured term loan facility with Silicon Valley Bank on April 18, 2025. The facility is structured in three tranches (Term A, B, and C) tied to specific dates and revenue milestones.
🚩 Red Flags
- The facility is secured by a pledge of substantially all company assets (excluding IP).
- Strict financial covenants: requires maintaining minimum net product revenue and a 'Minimum Cash Threshold' based on 6-month cash burn plus debt.
- Tranches B and C are contingent upon achieving specific revenue milestones, indicating the capital is not fully available upfront.
📋 Key Facts
- Total aggregate principal amount of up to $30 million.
- Tranche structure: Term A ($10M available Aug 2025), Term B ($10M based on net product revenue milestones), and Term C ($10M based on net product revenue milestones).
- Interest rate: Greater of WSJ Prime minus 0.25% (capped at 9.00%) or 6.00%.
- Maturity date is March 1, 2029.
- Security: Pledge of substantially all company assets, excluding intellectual property.
- Includes a 4.50% final payment fee at maturity/prepayment and tiered prepayment premiums (3.0% down to 0.0%).
- Requires maintenance of minimum net product revenue or specific EBITDA/cash thresholds.
Invivyd, Inc. announced the appointment of Ajay Royan to its Board of Directors, effective March 22, 2025. The filing details his compensation structure and indemnification agreement.
📋 Key Facts
- Ajay Royan appointed as a director effective March 22, 2025.
- Term expires at the Company's 2025 annual meeting of stockholders.
- Annual cash retainer set at $40,000.
- Granted nonqualified stock option for 100,000 shares vesting over three years (starting March 24, 2025).
- Standard indemnification agreement entered into with the new director.
Invivyd, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024. The filing serves as a formal announcement of earnings and business highlights via a press release.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024.
- Report date: March 20, 2025.
- The filing includes an earnings press release as Exhibit 99.1.
- Company is classified as an 'emerging growth company'.
Invivyd, Inc. issued a press release regarding the neutralizing activity of its product PEMGARDA™ (pemivibart) against the SARS-CoV-2 variant LP.8.1.
📋 Key Facts
- Date of event: March 5, 2025
- Subject matter: Neutralizing activity of PEMGARDA™ (pemivibart)
- Target: Currently dominant SARS-CoV-2 variant LP.8.1
- The filing is an Item 8.01 'Other Events' disclosure.
Invivyd, Inc. has regained compliance with Nasdaq's minimum bid price requirement after meeting the 10-consecutive-day closing price threshold of $1.00 per share. Additionally, the company reported that the FDA declined its request to expand the Emergency Use Authorization (EUA) for PEMGARDA™.
🚩 Red Flags
- FDA denial regarding expansion of PEMGARDA™ usage, which may impact future revenue potential for their primary therapeutic asset.
📋 Key Facts
- Nasdaq notified the Company on February 21, 2025, that it has regained compliance with Nasdaq Listing Rule 5450(a)(1).
- The company previously fell below the $1.00 minimum bid price requirement for 30 consecutive business days as of December 27, 2024.
- Compliance was achieved by maintaining a closing bid price of at least $1.00 per share for ten consecutive business days.
- The FDA declined the request to expand the PEMGARDA™ (pemivibart) EUA to include treatment of mild-to-moderate COVID-19 in immunocompromised persons.
Invivyd, Inc. released preliminary fourth quarter 2024 financial results alongside positive Phase 1/2 clinical data for its monoclonal antibody VYD2311. The company reported strong revenue growth and reiterated a goal of achieving near-term profitability.
🚩 Red Flags
- Financial results are preliminary and subject to change upon completion of closing controls; they have not been audited by independent public accounting firm.
📋 Key Facts
- Released preliminary Q4 2024 financial results on February 3, 2025.
- Reported 'strong revenue growth' for PEMGARDA™ (pemivibart) net product revenue in Q4 2024.
- Announced positive Phase 1/2 clinical data for VYD2311, a monoclonal antibody intended as a COVID-19 alternative.
- Reiterated the corporate goal of achieving near-term profitability.
Invivyd, Inc. issued a press release regarding positive SARS-CoV-2 variant data analysis intended to satisfy a U.S. FDA gating request for the Emergency Use Authorization (EUA) review of PEMGARDA™.
📋 Key Facts
- Company provided additional SARS-CoV-2 variant data analysis as requested by the FDA.
- The data is part of an EUA request for PEMGARDA™ (pemivibart).
- Target indication: Treatment of mild-to-moderate COVID-19 in certain immunocompromised patients.
- Filing date: January 27, 2025.
Invivyd, Inc. issued an 8-K to announce positive preclinical data regarding the neutralizing activity of its product PEMGARDA™ (pemivibart) against the SARS-CoV-2 Variant XEC.
📋 Key Facts
- Date of announcement: January 10, 2025
- Subject matter: Continued neutralizing activity of PEMGARDA™ (pemivibart)
- Target variant: Dominant SARS-CoV-2 Variant XEC
- Filing type: Item 8.01 (Other Events) via press release
Invivyd, Inc. received a deficiency letter from Nasdaq because its common stock closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until June 25, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice/deficiency letter from Nasdaq
- Failure to meet minimum bid price requirement ($1.00)
- Risk of delisting if compliance is not met by June 25, 2025
📋 Key Facts
- Received a deficiency letter from Nasdaq on December 27, 2024.
- The bid price closed below $1.00 for the previous 30 consecutive business days.
- The company has a 180-day compliance period ending June 25, 2025, to regain compliance by maintaining a $1.00 closing bid price for at least ten consecutive business days.
- A second 180-day extension may be available if the company transfers to the Nasdaq Capital Market and meets specific market value requirements.
Invivyd, Inc. announced the immediate resignation of Sara Cotter from its Board of Directors and all associated committees, effective November 27, 2024.
📋 Key Facts
- Sara Cotter resigned from the Board of Directors on November 27, 2024.
- The resignation is effective immediately.
- The departure includes her resignation from all committees of the Board.
Invivyd, Inc. released its quarterly financial results for the period ending September 30, 2024, and provided updates regarding clinical/regulatory commentary in the New England Journal of Medicine.
📋 Key Facts
- Company reported financial results for the quarter ended September 30, 2024 (Item 2.02).
- Issued a press release regarding a New England Journal of Medicine letter highlighting the immunobridging pathway for PEMGARDA™ (pemivibart) Emergency Use Authorization.
- Updated its corporate presentation on the company website.
Invivyd, Inc. reported preliminary Q3 2024 financial results and simultaneously withdrew its prior full-year financial guidance. The company also released positive Phase 3 long-term efficacy data for its product PEMGARDA™.
🚩 Red Flags
- Withdrawal of prior financial guidance (significant indicator of volatility or missed expectations).
- Reliance on preliminary, unaudited financial data for market updates.
- High uncertainty regarding future revenue trajectories given the guidance withdrawal.
📋 Key Facts
- Company issued preliminary Q3 2024 net product revenue estimates for PEMGARDA™ (pemivibart).
- Management officially withdrew previously issued financial guidance.
- Released Phase 3 long-term exploratory clinical efficacy data showing substantial protection from symptomatic COVID-19 over six months of follow-up with no additional doses.
- Preliminary financial data is unaudited and has not been reviewed by PricewaterhouseCoopers LLP.
Invivyd, Inc. issued an 8-K to announce a press release containing detailed virology data and structural biology analysis for its product PEMGARDA™ (pemivibart). The filing focuses on predicting the neutralization activity of the candidate against SARS-CoV-2.
📋 Key Facts
- Date of report: September 23, 2024
- Subject matter: Virology data and structural biology analysis for PEMGARDA™ (pemivibart)
- Focus: Predicting anticipated neutralization activity against SARS-CoV-2
- The filing incorporates a press release as Exhibit 99.1
Invivyd, Inc. filed an 8-K to announce the posting of an updated corporate presentation on its website. This is a routine disclosure often used by biotech companies to communicate recent developments or strategic updates to investors.
📋 Key Facts
- The company posted an updated corporate presentation on September 6, 2024.
- The presentation is filed as Exhibit 99.1.
- The filing was signed by Jill Andersen, Chief Legal Officer and Corporate Secretary.
Invivyd, Inc. issued a press release announcing the dosing of the first participants in its Phase 1 clinical trial for VYD2311, a next-generation monoclonal antibody candidate for COVID-19.
📋 Key Facts
- Company has commenced dosing for the Phase 1 clinical trial of VYD2311.
- VYD2311 is described as a 'next generation' monoclonal antibody candidate for COVID-19.
- The development builds upon the company's previous product, PEMGARDA™.
Invivyd, Inc. issued a press release regarding the neutralizing activity of its product PEMGARDA™ (pemivibart) against specific SARS-CoV-2 variants including KP.3.1.1 and LB.1.
📋 Key Facts
- Date of event: September 3, 2024
- Subject matter: Continued neutralizing activity of PEMGARDA™ (pemivibart) against dominant SARS-CoV-2 variants KP.3.1.1 and LB.1.
- The filing incorporates a press release as Exhibit 99.1.
Invivyd, Inc. issued a press release announcing positive exploratory data from its ongoing CANOPY Phase 3 clinical trial for PEMGARDA (pemivibart). The analysis showed an 84% relative risk reduction in symptomatic COVID-19 compared to placebo.
📋 Key Facts
- Announced exploratory analysis results from the ongoing CANOPY Phase 3 Clinical Trial on August 27, 2024.
- PEMGARDA (pemivibart) demonstrated an 84% relative risk reduction in symptomatic COVID-19 compared to placebo.
- The company updated its corporate presentation and issued a press release as part of this disclosure.
Invivyd, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024, and provided an updated corporate presentation.
📋 Key Facts
- Reported quarterly financial results for the period ending June 30, 2024.
- Issued a new corporate presentation via Exhibit 99.2.
- The filing includes a press release as Exhibit 99.1.
Invivyd, Inc. issued a press release announcing positive antiviral activity of its candidate VYD222 (pemivibart) against the SARS-CoV-2 KP.1.1 FLiRT and KP.3 variants.
📋 Key Facts
- Announcement date: June 14, 2024
- Subject matter: Antiviral activity of VYD222 (pemivibart)
- Targeted variants: SARS-CoV-2 KP.1.1 FLiRT and KP.3
- Filing type: Item 8.01 (Other Events) via press release
Invivyd, Inc. announced the departure of interim CEO, COO, and CCO Jeremy Gowler, effective May 30, 2024. CFO William Duke, Jr. will step in as Principal Executive Officer while the company searches for a permanent CEO.
🚩 Red Flags
- Leadership instability: Departure of the interim CEO/COO/CCO creates a vacuum in top management during a transition period.
- Management turnover: Multiple changes to the executive suite (CEO, CCO) occurring simultaneously.
📋 Key Facts
- Jeremy Gowler ceased serving as Interim CEO, COO, and CCO on May 30, 2024; employment terminates June 29, 2024.
- William Duke, Jr. (current CFO) appointed as Principal Executive Officer, effective May 30, 2024.
- Timothy Lee appointed as Chief Commercial Officer per press release dated May 31, 2024.
- The company is actively searching for a permanent CEO.
- Company announced alignment with the FDA on an immunobridging pathway for COVID-19 monoclonal antibodies.
Invivyd, Inc. reported the results of its Annual Meeting of Stockholders held on May 21, 2024. The meeting included the election of seven directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2024.
📋 Key Facts
- Annual Meeting held on May 21, 2024.
- Seven directors elected: Tamsin Berry, Sara Cotter, Marc Elia, Srishti Gupta, M.D., Christine Lindenboom, Terrance McGuire, and Kevin McLaughlin.
- PricewaterhouseCoopers LLP (PwC) ratified as independent registered public accounting firm for the fiscal year ending Dec 31, 2024.
- The company issued a press release on May 22, 2024, regarding two new independent members to its Board of Directors.
Invivyd, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024 and provided an updated corporate presentation.
📋 Key Facts
- Reported financial results for the fiscal quarter ending March 31, 2024 via press release (Exhibit 99.1).
- Released an updated corporate presentation on the company website (Exhibit 99.2).
- Filed under Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events).
Invivyd, Inc. announced its intent to pursue a rapid immunobridging pathway for an Emergency Use Authorization (EUA) to treat COVID-19 in immunocompromised patients following feedback from the U.S. FDA.
🚩 Red Flags
- Regulatory uncertainty inherent in seeking EUA pathways for specific patient subpopulations.
📋 Key Facts
- Company is pursuing a 'rapid immunobridging pathway' for potential EUA.
- Target population: Moderately to severely immunocompromised people with COVID-19.
- The strategy is based on recent feedback received from the U.S. FDA.
- Filing date: May 7, 2024.
Invivyd, Inc. announced the departure of CEO David Hering, effective April 11, 2024, and his resignation from the Board. Jeremy Gowler, currently the COO and CCO, has been appointed as Interim CEO while a search for a permanent successor is conducted.
🚩 Red Flags
- Sudden departure of the Chief Executive Officer and Director.
- Management instability during a transition period.
- Reduction in Board size coinciding with CEO departure.
📋 Key Facts
- CEO David Hering ceased serving as executive officer effective April 11, 2024; employment terminates May 11, 2024.
- David Hering has resigned from the Board of Directors.
- The Board size was reduced from nine members to eight members.
- Jeremy Gowler (COO/CCO) appointed as Interim CEO and Principal Executive Officer effective April 11, 2024.
- Interim CEO compensation includes an additional $5,000 monthly payment.
- The Board has instituted a search for a permanent CEO successor.
Invivyd, Inc. issued a press release providing a launch update for its product PEMGARDA™ and announced 2024 net product revenue guidance in the range of $150 million to $200 million.
📋 Key Facts
- Announced 2024 Net Product Revenue Guidance: $150 million to $200 million.
- Provided a launch update for PEMGARDA™ product.
- Updated corporate presentation released on April 4, 2024.
Invivyd, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023, and provided recent business highlights via a press release.
📋 Key Facts
- Report date: March 28, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes an earnings press release as Exhibit 99.1
- The company is classified as an emerging growth company
Invivyd, Inc. announced FDA Emergency Use Authorization (EUA) for PEMGARDA™ (formerly VYD222) for COVID-19 pre-exposure prophylaxis and released interim exploratory data from its CANOPY clinical trial.
🚩 Red Flags
- Cash position figures provided are preliminary and subject to change upon completion of audited financial statements.
📋 Key Facts
- FDA has authorized the emergency use of PEMGARDA™ (formerly VYD222) for COVID-19 Pre-exposure Prophylaxis (PrEP).
- The company released interim exploratory data from the ongoing CANOPY Clinical Trial regarding VYD222.
- The filing includes preliminary, unaudited cash and cash equivalents as of December 31, 2023.
- An updated corporate presentation was published on the company website.
The filing appears to be a technical data dump of XBRL taxonomy elements and metadata rather than a substantive narrative 8-K report. It contains extensive lists of accounting members, dates (ranging from 2020 to 2024), and financial instrument identifiers.
🚩 Red Flags
- The provided text is a non-narrative metadata dump, making it impossible to assess actual material events or financial health from this specific text block.
📋 Key Facts
- Filing date: February 9, 2024
- Contains a high volume of XBRL taxonomy tags related to equity (Series A, B, C Preferred Stock)
- Includes references to various research agreements including Adimab and Scripps Research Institute
- Lists significant R&D expense categories and in-process research and development items
- References multiple employee incentive plans and stock purchase plans
Invivyd, Inc. filed an 8-K to announce the posting of an updated corporate presentation on its website as of January 8, 2024.
📋 Key Facts
- The company released an updated corporate presentation via Exhibit 99.1.
- The filing is categorized under Item 8.01 (Other Events).
- The report was signed by Jill Andersen, Chief Legal Officer and Corporate Secretary.
Invivyd, Inc. announced that it has submitted a request for Emergency Use Authorization (EUA) to the U.S. FDA for its product VYD222. The application seeks authorization for the pre-exposure prevention of COVID-19 in immunocompromised adults and adolescents.
📋 Key Facts
- Date of event: January 3, 2024
- Action: Submitted EUA request to U.S. FDA
- Product: VYD222
- Target Indication: Pre-exposure prevention of COVID-19 in immunocompromised adults and adolescents